Note: 2018 and 3Q20 net profits include special items
  Consolidated financial statements
Profit and loss statements (million baht) 2019 2020 2Q21 % YoY change
Revenue from medical service 7,461 6,913 1,797 19.4%
Revenue from Healthcare solution provider 756 386 102 41.7%
Revenue from other businesses 15 16 7 133.3%
Total revenue 8,232 7,315 1,906 20.6%
Cost from medical service (5,861) (5,459) (1,330) 5.8%
Cost from Healthcare solution provider (492) (278) (79) 58.0%
Cost from other businesses (13) (11) (4) 33.3%
Total cost (6,366) (5,748) (1,413) 7.9%
Gross profit 1,866 1,567 493 82.6%
Selling, general and admin expenses (1,397) (1,405) (342) -0.3%
EBITDA 1,419 1,157 402 221.6%
Normalized EBITDA 1,236 1,138 411 228.8%
Financial cost (216) (281) (72) 12.5%
Net profit  459 22 72 149.7%
Normalized net profit 314 (63) 79 154.5%
Net profit - parent 462 62 84 166.7%
Normalized net profit - parent 311 (23) 91 172.2%
Margin 2019 2020 2Q21  
Gross profit margin 22.7% 21.4% 25.9%
EBITDA margin 17.2% 15.8% 21.1%
Normalized EBITDA margin 15.0% 15.6% 21.6%
Net profit margin - parent 5.6% 0.9% 4.4%
Normalized net profit margin - parent 3.8% -0.3% 4.8%
Statements of financial position (million baht) End of 2019 End of 2020 End of 2Q21 % change from end of 2020
Current assets 5,025 4,892 5,213 6.6%
Non-current assets 15,260 15,388 15,397 0.1%
Total assets 20,285 20,280 20,610 1.6%
Current liabilities 5,127 5,043 6,235 23.6%
Non-current liabilities 6,376 6,906 6,397 -7.4%
Total liabilities 11,503 11,949 12,632 5.7%
Total equity 8,782 8,331 7,978 -4.2%
Financial ratios 2019 2020 2Q21
Current ratio (times) 1.0 1.0 0.8
Return on assets (%) 4.2 1.6 1.7
Assets turnover (times) 0.5 0.4 0.4
Return on equity (%) 5.6 0.8 (0.3)
Debt/ equity (times) 1.3 1.5 1.7
Interest bearing debt/ EBITDA (times) 6.3 8.7 8.6
Debt service coverage ratio (DSCR) (times)  2.2 1.4 1.0
Interest coverage ratios (times) 3.7 1.2 0.2

Note: normalized values (before tax) exclude

1) Profit from the disposal of investment in Ratchathanee PLC in 2Q19 amounting to THB278mn
2) Reserve for employees’ benefit in 2Q19 amounting to THB96mn for Consolidated financial statements and THB78mn for separate financial statement
3) Profit from disposal of JV investment in Welly Hospital, China of THB19mn in 1Q20 for Consolidated financial statements and loss from the disposal of the investment of THB236mn for separate financial statement in 1Q20
4) Income from deferred tax from JV in Welly Hospital, China of THB67mn in 1Q20
5) Reverse allowance for doubtful accounts of interest receivable-related companies amounting to THB45mn in 2Q20
6) Expenses from the end of a management contract with a government hospital (net corporate income tax) of THB7mn in 2Q21